Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
T5O | Xetra | EUR | Delayed | |
T5O | TradeGate | EUR | Delayed | |
T5O | Frankfurt | EUR | Delayed |
bioXXmed AG, formerly CytoTools AG, is a Germany-based holding company that invests in biotechnological or medical technology companies with equity or borrowed capital. The Company holds interests in research and development (R&D) companies DermaTools Biotech GmbH, which is active in the field of dermatology and urology, and CytoPharma GmbH, which is engaged in product development for cardiovascular diseases, cancer and other indications. bioXXmed AG manages the patent portfolio and coordinates the licensing for its subsidiaries. The product pipeline of disease modifying therapies based on the mechanisms of cell growth and programmed cell death, comprising small molecules and biologics across a range of disease indications, includes DermaPro, the Company's lead product indicated for diabetic and venous foot ulcers in phase III of clinical trials, as well as Utisept, an urological medical device for flushing the bladder in urinary tract infections.
Name | Age | Since | Title |
---|---|---|---|
Soren Rose | - | - | Supervisory Board Member |
Ronald Beckerbauer | - | - | Supervisory Board Member |
Alexander Link | - | 2024 | Member of Supervisory Board |
Daniel Vogel | - | 2024 | Chairman of Supervisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review